Although oxaliplatin is an effective anti-cancer platinum compound, it can cause painful chronic neuropathy, and its molecular mechanisms are poorly understood. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Although miRNAs have been increasingly recognized as important modulators in a variety of pain conditions, their involvement in chemotherapy-induced neuropathic pain is unknown.
Introduction
Peripheral neuropathy is a major dose-limiting adverse effect of several anti-cancer drugs, including platinum compounds (Kim et al., 2015) . Patients may experience setbacks in chemotherapy due to peripheral neuropathy, such as being required to decrease their drug dose or frequency, or to switch to other drugs, which can negatively affect the outcome of cancer management (Albers et al., 2014) . Oxaliplatin, a third-generation platinum compound, is a key drug used in the treatment of colorectal cancer. However, it can cause two forms of peripheral neuropathy, acute and chronic neuropathy. Acute symptoms appear immediately after oxaliplatin administration and include distal and perioral paresthesia and muscle fasciculation. These symptoms are characteristically triggered by cold stimulation and mediated, at least in part, by transient receptor potential (TRP)A1 and TRPM8 receptors (Kono et al., 2012; Ewertz et al., 2015; Yamamoto et al., 2015) . When oxaliplatin causes chronic neuropathy, pain is the most common and severe complaint reported. However, the molecular mechanisms underlying the development of chronic neuropathic pain remain poorly understood.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by recognizing the 3 0 untranslated regions (UTRs) of mRNAs in a sequence-specific manner and are, therefore, closely involved in diverse pathological conditions, including cancers (Bartel, 2009) . Similarly, a variety of miRNAs are causally involved in painful conditions with distinct aetiologies, such as tissue inflammation and traumatic nerve injury (Sakai and Suzuki, 2014) . Because the miRNA expression profile extensively varies with the underlying causes, distinct miRNAs appear to be responsible for different pain conditions. Nevertheless, the involvement of miRNA in chemotherapy-induced neuropathic pain has not been reported, although miRNAs have received much attention as therapeutic targets for both pain and cancers.
The miRNA miR-15b is a member of miR-15/107 family, which has a similar sequence in the target-recognizing seed sequence. This miRNA family is implicated in playing a role in cancers and neurodegenerative diseases (Finnerty et al., 2010) and has been shown to target the aspartyl protease β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) (Parsi et al., 2015) . In the present study, we found that miR15b expression was up-regulated in dorsal root ganglion (DRG) neurons following oxaliplatin administration and caused hypersensitivity to mechanical stimuli, possibly through an effect on BACE1.
Methods

Animal model
All experimental procedures were approved by the Animal Experiments Ethical Review Committee of Nippon Medical School (approval number 27-037) and performed in accordance with the guidelines of the International Association for the Study of Pain (Zimmermann, 1983) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . A total of 110 male Sprague-Dawley rats (6-7 weeks; 160-230 g; Sankyo Labo Service Corporation, Tokyo, Japan) were randomly subjected to the treatments used in the present study. Rats were housed with access to food and water ad libitum. All surgeries were performed under deep anaesthesia induced by an i.p. injection of sodium pentobarbital (50 mg·kg À1 ) or by isoflurane inhalation (2-3%). Rats were killed by exsanguination when under deep anaesthesia. To produce oxaliplatin-induced peripheral neuropathy, a stock solution of oxaliplatin was diluted with 5% glucose solution (2 mg·mL À1 ) and injected i.p. at a dose of 2 mg·kg À1 for five consecutive days. This rat model of pain has been in use for several years (Zheng et al., 2011) . Control animals were injected with vehicle
was dissolved in 6.7% DMSO and 5% Tween 20 in saline and was injected i.p. at a dose of 10 mg·kg À1 . Vehicle was injected as a control.
To inject adeno-associated virus (AAV) vectors, the paraspinal muscles were separated from the vertebrae, and a small part of the vertebra overlying the fifth lumbar (L5) DRG was removed to expose the ganglion. The AAV vector (5 μL) was slowly injected into the L5 DRG using a microsyringe with a 27-gauge needle. This focal AAV6 vector injection was previously shown to introduce transgenes specifically into L5 DRG neurons of all sizes (Sakai et al., 2013) . The in vivo transduction of the AAV vectors into the DRG neurons was confirmed using an enhanced green fluorescent protein (EGFP) immunofluorescence assay.
Behavioural test
Paw withdrawal responses to mechanical stimuli were measured using a set of von Frey filaments (Muromachi Kikai, Tokyo, Japan). Each rat was placed on a metallic mesh floor covered with a plastic box, and a von Frey filament was applied from underneath the mesh floor to the plantar surface of the hind paw. The weakest force (g) inducing withdrawal of the stimulated paw at least three times in five trials was referred to as the paw withdrawal threshold. These behavioural tests were assessed by an investigator blinded to the treatments of the rats.
Quantitative PCR
For quantitative PCR analysis, all procedures were performed according to the manufactures' protocols. Total RNA was extracted from the L5 DRG using RNAiso Plus (Takara Bio, Shiga, Japan). Total RNA (10 ng) was reverse-transcribed with a mature miR-15b-specific stem-loop primer using a TaqMan MicroRNA Reverse Transcription kit. PCR mixtures were prepared with TaqMan Universal PCR Master Mix and miR15b-specific TaqMan probe and primers included in the TaqMan MicroRNA Assays. PCR amplifications were performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The amplification efficiency for one PCR cycle was obtained by assaying serially diluted samples (four points at dilutions of 1:5), and the relative expression was calculated.
Plasmids
To produce an AAV plasmid vector expressing miR-15b (pAAV-miR-15b), miR-15b and its flanking region were amplified from the rat genome using forward (5 0 -CCATGGGATTGACTTAGACC-3 0 ) and reverse (5 0 -CCCTGTCACACTAAAGCAG-3 0 ) primers with EcoRI restriction sites attached at the 5 0 ends. The amplified DNA fragment was subcloned into the EcoRI site of the AAV vector plasmid pAAV/ASA (Miyake et al., 2014) , which contains a CAG promoter upstream of the transgene and an EGFP gene driven by the B19 promoter. As a control, pAAV-EGFP (Noro et al., 2004) , which expresses EGFP driven by a CAG promoter, was used.
A plasmid vector encoding firefly luciferase followed by BACE1 3 0 -UTR was constructed. The BACE1 3 0 -UTR sequence was amplified from rat DRG-derived cDNA. A forward (5 0 -GGAGGCCAGTGGGCAGATGA-3 0 ) and reverse (5 0 -CCTCAGCCCTACAATATTCT-3 0 ) primer pair with SpeI restriction sites attached at the 5 0 ends was used. The PCR products were subcloned into the SpeI site after the luciferase gene of the pMIR-REPORTER. The miR-15b seed sequence within the 3 0 -UTR sequence was mutated using a QuikChange II XL Site-Directed Mutagenesis kit and the primers 5 0 -GTCAGGGCTGAAGCTTAAGGTGCAACATTTCC-AACTCAAG-3 0 and 5 0 -CTTGAGTTGGAAATGTTGCACCTTA-AGCTTCAGCCCTGAC-3 0 .
AAV vector production
Serotype 6 AAV vectors were produced by adenovirus-free triple transfection with AAV vector, AAV packaging (pRepCap 6as, provided by DW Russell) (Rutledge et al., 1998) and helper plasmids (pHelper) at a ratio of 1:1:1. For miR15b-expression and control AAV vectors, plasmids were co-transfected into HEK293 cells using calcium phosphate precipitation as previously described (Miyake et al., 2012) . Six hours after transfection, the culture medium was replaced with fresh medium, and cells were then cultured for 3 days at 37°C under 5% CO 2 in a humidified atmosphere. Cells were suspended in PBS and freeze-thawed three times. Cell debris was pelleted at 6500 x g for 30 min at 4°C, and AAV vectors were purified by ammonium sulphate precipitation and iodixanol continuous gradient centrifugation. 
Immunofluorescence
The L5 DRG sections were pre-incubated in PBS containing 5% normal donkey serum and 0.2% Triton X-100 for 30 min and then incubated with rabbit anti-GFP antibody (1:1000) at 4°C overnight. Sections were washed in PBS and then incubated with a secondary antibody labelled with Alexa Fluor 488 at room temperature for 1 h. Images were captured using a high-resolution digital camera equipped with a computer (Olympus, Tokyo, Japan).
Luciferase assay
The activities of firefly and Renilla luciferases were measured using the Dual-Glo Luciferase Assay System. The HEK293T cells were seeded onto a 96-well plate (2 × 10 4 cells per well).
The next day, cells were co-transfected with pMIR luciferase reporter, pGL4.74[hRluc/TK] and pAAV-miR-15b using Lipofectamine 2000. Two days after transfection, Dual-Glo luciferase reagent was added to each well, and firefly luminescence was measured using a Wallac 1420 ARVO MX plate reader (PerkinElmer, Waltham MA). Then, Dual-Glo Stop & Glo reagent was added to each well, and Renilla luminescence was measured. Firefly luminescence was divided by Renilla luminescence and then the luminescence of control pMIR for normalization.
RT-PCR of microdissected samples
Single cells were obtained by laser capture microdissection. The L5 DRG was excised under isoflurane anaesthesia and then rapidly frozen in OCT compound using dry ice/acetone. The DRG was sectioned (20 μm) using a cryostat (Leica, Wetzlar, Germany), and sections were mounted onto RNase-free PEN membrane glass slides (Leica). The sections were incubated in RNAlater solution for 2 min at room temperature. After being washed with RNase-free water for 1 min on ice, the sections were stained with toluidine blue (0.05%, pH 4.1) for 15 s on ice to visualize the DRG neurons. After again being washed with RNase-free water for 1 min on ice, the sections were dried with a hair drier. Single DRG neurons were obtained using a laser microdissection system (LMD7000; Leica) and were processed with a Single Cell-to-CT kit according to the corresponding manufacturer's protocol (Thermo Fisher Scientific). The single DRG neuron was lysed, and the DNA was degraded with DNase I. Reverse transcription reaction of the lysed sample for BACE1 analysis was performed using reagents in the Single Cell-to-CT kit, and the reaction for miR-15b was performed using a TaqMan MicroRNA Reverse Transcription Kit and mature miRNAspecific stem-loop primers, including miR-15b (TaqMan MicroRNA Assays). The reverse transcription product was pre-amplified using cocktails supplied in the TaqMan Gene Expression assays for BACE1, or those supplied in the TaqMan MicroRNA assays for miRNA-specific primer pairs (including miR-15b). PCR amplification of the diluted pre-BJP N Ito et al.
amplified product was conducted as described in the Quantitative PCR section. Signal intensity was considered positively detected when it was 10-fold greater than that of the negative control.
Immunoblotting
The L5 DRG was sonicated in 10 mM Tris-HCl (pH 7.2) containing 250 mM sucrose, 10 mM HEPES, 10 mM EDTA and protease inhibitor cocktail or was homogenized in the Cell Suspension buffer contained in the mirVana PARIS kit. Tissue lysates were centrifuged at 13 000 × g and 4°C for 20 min. Supernatants were electrophoresed on SDS-PAGEs and electroblotted onto PVDF membranes (GE Healthcare Life Sciences, Pittsburgh, PA). Membranes were incubated with an anti-BACE1 (1:200) or an anti-GAPDH (1:1000) antibody at 4°C overnight followed by horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000). Membranes were then processed for chemiluminescence (ECL Prime Western Blotting Detection Reagents), which was detected by a C-DiGit Blot Scanner (LI-COR Biotechnology, Lincoln, NE). GAPDH was used as a loading standard. Optical densities of bands were quantified using ImageJ (National Institutes of Health, Bethesda, MD). 
Data and statistical analyses
Results
miR-15b expression is up-regulated in the DRG in oxaliplatin-induced neuropathy
Oxaliplatin administration for five consecutive days caused significant mechanical allodynia that appeared 7 days after the first injection and persisted for at least 28 days ( Figure 1A ). To examine the involvement of miRNAs in oxaliplatin-induced chronic neuropathy, a main doselimiting factor in clinical practice, miRNA expression levels were assessed 28 days after the first oxaliplatin administration. We first addressed the expression changes of several miRNAs up-regulated in the DRG after nerve injury that we had observed in our previous study (Sakai et al., 2013) . Among the miRNAs examined, miR-15b was most robustly up-regulated in the L5 DRG ( Figure 1B ). We next determined the time course for the miR-15b expression change. The expression level of miR-15b was not significantly altered in the early phase of oxaliplatin-induced peripheral neuropathy, whereas it was significantly increased in the late phase ( Figure 1C ).
miR-15b overexpression causes mechanical allodynia
To examine the involvement of miR-15b in mechanical allodynia, we increased the expression of miR-15b in the DRG neurons of intact rats using a serotype 6 AAV vector. Injection of the AAV vector encoding both miR-15b and EGFP into the L5 DRG induced EGFP expression in L5 DRG neurons of all sizes 7 days after the injection (Figure 2A ), as previously shown (Towne et al., 2009) . The AAV vector injection also increased miR-15b expression ( Figure 2B ), and miR-15b overexpression caused significant mechanical allodynia in intact rats ( Figure 2C ).
miR-15b targets the 3 0 -UTR of BACE1
Because miRNAs block the translation of certain mRNAs by binding to their 3 0 -UTR sequences, we searched for potential candidate genes targeted by miR-15b using TargetScan (http://www.targetscan.org). Among the predicted targets, we focused on BACE1 because BACE1-null mice show an increased sensitivity to pain (Hu et al., 2006) . We first determined whether miR-15b actually targeted the 3 0 -UTR sequences of Bace1 mRNA. The Bace1 3 0 -UTR sequence was inserted downstream of the luciferase gene in a plasmid vector. The activity of luciferase with the Bace1 3 0 -UTR sequence was consistently decreased by miR-15b ( Figure 3A) . To identify the miR-15b binding sequence within the 3 0 -UTR, we mutated the predicted Bace1 seed sequences. The activity of luciferase with a mutated 3 0 -UTR sequence was no longer decreased by miR-15b ( Figure 3A) . Furthermore, the miR-15b binding sites were well conserved among mammals ( Figure 3B) .
A single DRG neuron captured using laser microdissection was analysed to examine the expression profiles of miR-15b Figure 1 miR-15b expression is increased in the chronic neuropathic pain observed following oxaliplatin administration. (A) Paw withdrawal responses to mechanical stimuli were evaluated before and after vehicle (n = 10) or oxaliplatin (n = 9) injection for five consecutive days. *P < 0.05 versus the value of vehicle by the Mann-Whitney U-test. (B) Expression levels of the miRNAs that were up-regulated after traumatic nerve injury in our previous study (Sakai et al., 2013) were examined in the L5 DRG 28 days after the first oxaliplatin injection (n = 5). (C) Expression levels of miR-15b in the L5 DRG on the indicated days after the first oxaliplatin injection (n = 5 for days 7, 14 and 21; n = 6 for day 28). *P < 0.05 by Student's unpaired t-test.
Figure 2
Overexpression of miR-15b in DRG neurons causes mechanical allodynia. (A) Representative image of EGFP immunofluorescence in the intact L5 DRG 7 days after AAV vector injection. Scale bar, 100 μm. (B) Levels of miR-15b expression were examined in the L5 DRG 7 days after control (n = 6) or miR-15b (n = 7) AAV injection. *P < 0.05, by Student's unpaired t-test. (C) Paw withdrawal thresholds in response to mechanical stimuli were evaluated 7 days after the AAV injection. *P < 0.05 by the Mann-Whitney U-test (n = 5).
and BACE1 in L5 DRG neurons. The expression of BACE1 and miR-15b was detected using RT-PCR in both small-sized cells, putative non-myelinated C-fibre neurons, and in medium/large-sized cells, putative myelinated A-fibre DRG neurons ( Figure 3C ). The miR-15b expression was detected in five out of eight BACE1-positive DRG neurons.
BACE1 is down-regulated in the DRG after oxaliplatin administration and miR-15b overexpression BACE1 protein expression was examined in the DRG following oxaliplatin administration. On day 28 after the first oxaliplatin injection, but not before day 28, BACE1 expression was significantly decreased in the DRG ( Figure 4A ). The overexpression of miR-15b in intact rats decreased BACE1 expression 7 days after the AAV injection ( Figure 4B ).
BACE1 inhibitor causes mechanical allodynia
To examine the effect of BACE1 inhibition on pain behaviour, the BACE1 inhibitor LY2886721 was injected i.p. into intact rats. LY2886721 (10 mg·kg À1 ) exerted no acute effect on paw withdrawal threshold to mechanical stimuli ( Figure 5A ). However, 6 h after the injection, LY2886721 caused persistent mechanical allodynia, which was no longer present 3 days after the injection ( Figure 5A ). This pronociceptive effect of LY2886721 occurred in a dosedependent manner ( Figure 5B ).
Discussion
In this study, miR-15b was up-regulated in DRG neurons in the late, but not early, phase of oxaliplatin-induced peripheral neuropathy. Because miR-15b overexpression alone was sufficient to cause significant mechanical allodynia in intact miR-15b mediates oxaliplatin-induced chronic pain BJP rats, miR-15b probably contributed to the chronic mechanical allodynia observed in oxaliplatin-induced neuropathy. In addition to causing mechanical allodynia, oxaliplatin reportedly induces chronic cold allodynia (Xiao et al., 2012) . In the present study, although we did not examine whether miR-15b up-regulation and subsequent BACE1 inhibition induced cold allodynia, the involvement of several molecules whose functions are regulated by BACE1 has been previously examined in this noxious cold sensation. For example, intrathecal injection of TNFα, whose receptor is regulated by BACE1, affects the response in the cold-plate test (Nakanishi et al., 2016) . The late onset of the increase in miR-15b expression suggests the specific contribution of miR-15b to the maintenance of oxaliplatin-induced neuropathic pain, although it remains unclear which factors induced increased miR-15b expression in the late phase. However, LPS has been shown to increase miR-15b expression in a trophoblast cell line (Yang et al., 2016) . Consistent with this result, LPS-activated intracellular signalling molecules, ERK and NFκB induce miR-15b expression through c-Rel and CREB in HeLa cells (Zhu et al., 2016) . The expression of miR-15b is also induced by platelet-derived growth factor in human pulmonary artery smooth muscle cells (Kim and Kang, 2013) .
BACE1 down-regulation by miR-15b contributes to the painful peripheral neuropathy induced by oxaliplatin, although other target genes may also be involved. We found that miR-15b was co-expressed in more than half of the DRG neurons expressing BACE1, and the time course for BACE1 down-regulation paralleled that for miR-15b upregulation after oxaliplatin injection, suggesting that miR15b can regulate BACE1 expression in a cell-autonomous manner. Our results indicate that miR-15b directly targeted the 3 0 -UTR sequence of BACE1 because the mutated BACE1 3 0 -UTR sequence was no longer decreased by miR-15b. The conservation of target 3 0 -UTR sequences among mammals observed in the present study suggested the functional importance of BACE1 regulation by miR-15b. Consistent with this result, miR-15b overexpression or oxaliplatin administration decreased BACE1 expression in DRG neurons in vivo. Furthermore, systemic administration of the BACE1 inhibitor induced mechanical allodynia. BACE1 is a membraneanchored aspartyl protease that cleaves a variety of substrates involved in neuronal functions, including myelination (Kuhn et al., 2012; Vassar et al., 2014; Barão et al., 2016) . Indeed, BACE1 expression was detected in the present study in putative myelinated DRG neurons. It was previously reported that BACE1-null mice show hypomyelination of sciatic nerves (Hu et al., 2006) . BACE1 expression was also detected in the present study in the small DRG neurons that are generally thought to represent non-myelinated nociceptive neurons. Thus, BACE1 may contribute not only to the myelination but also to the nociception of peripheral sensory neurons.
Neuregulin 1 (NRG1) is the best characterized substrate of BACE1 in peripheral neurons. BACE1-mediated processing of NRG1 leads to its interaction with neighbouring ErbB family receptors, which are expressed in Schwann cells. Interestingly, oxaliplatin was reported to reduce NRG1 expression in the sciatic nerve (Tsutsumi et al., 2014) . Reduced axonal NRG1 causes a decrease in the nerve conduction velocity that is associated with hypomyelination in sciatic nerves (Michailov et al., 2004) . Transgenic mice expressing dominant-negative ErbB-4 in myelinating cells, such as Schwann cells, also display hypomyelination in peripheral sensory axons . However, the roles of NRG1 in nociception are conflicting. Dominant-negative ErbB-4 mice exhibit hypersensitivity to mechanical, but not thermal, stimulation, although a causal relationship of the hypomyelination to mechanical pain has not yet been shown. By contrast, NRG1 ablation results in reduced sensitivity to noxious mechanical stimuli (Fricker et al., 2009) .
BACE1 may also contribute to oxaliplatin-induced peripheral neuropathy through other mechanisms. BACE1 is known to cleave the Na V β2 subunit (Wong et al., 2005; Gersbacher et al., 2010) , which regulates cell surface
Figure 4
Oxaliplatin and miR-15b reduce BACE1 protein expression. (A, B) Expression levels of BACE1 protein in the L5 DRG after vehicle (Veh) or oxaliplatin (Oxa) injections on the indicated days (A; n = 5), and 7 days after control (B; n = 5) or miR-15b (B; n = 6) AAV injections. GAPDH was used as a loading standard. *P < 0.05 by Student's unpaired t-test. Kim et al., 2007) . BACE1-null mice show neuronal hyperexcitability associated with increased sodium channel activity (Hu et al., 2010) . In addition, Na V β2-null mice show less severe neuropathic pain after traumatic nerve injury (Pertin et al., 2005) . BACE1 was also reported to modulate the expression of TNF receptor 1 (TNFR1), which is a critical mediator of inflammatory processes. TNFR1 expression is increased in BACE1 knockout mice and by a BACE1 inhibitor in wild-type mice independent of the proteolysis of the receptor .
In conclusion, our results indicated that miR-15b-mediated BACE1 down-regulation may contribute to the pain observed in the chronic phase of oxaliplatin-induced peripheral neuropathy. 
